JPH11500409A - ワクチン組成物用アジュバント - Google Patents
ワクチン組成物用アジュバントInfo
- Publication number
- JPH11500409A JPH11500409A JP8515800A JP51580096A JPH11500409A JP H11500409 A JPH11500409 A JP H11500409A JP 8515800 A JP8515800 A JP 8515800A JP 51580096 A JP51580096 A JP 51580096A JP H11500409 A JPH11500409 A JP H11500409A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- amphiphilic compound
- group
- antigen
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.カチオン性基に結合したステロール由来の親油基を含む両親媒性化合物のワ クチン組成物製造における利用。 2.親油性基がコレステロール誘導体である請求項1に記載の利用。 3.カチオン性基が第4級アンモニウムまたはプロトン化可能なアミンである請 求項1または2に記載の利用。 4.親油性基がエステル、エーテル、アミドまたはカルバモイル結合によってカ チオン性基に結合されている請求項1〜3のいずれか一項に記載の利用。 5.親油性基とカチオン性基との間が1〜20個の炭素原子を含む分岐鎖を有する か有しないアルキル鎖で隔てられている請求項1〜4のいずれか一項に記載の利 用。 6.両親媒性化合物が下記(a)〜(e)から選択される請求項1〜5のいずれか一項 に記載の利用: (a) コレステリル-3β- カルボキサミドエチレントリメチルアンモニウムアイオ ダイド (b) コレステリル-3β- カルボキサミドエチレナミン (c) コレステリル-3β- オキシスクシナミドエチレントリメチルアンモニウムア イオダイド (d) 3β-[N-(N',N'- ジメチルアミノエタン)カルバモイル]- コレステロール、 (e) 3β-[N-( ポリエチレナミン)カルバモイル]コレステロール。 7.3β-[N-(N',N'- ジメチルアミノエタン)カルバモイル]-コレステロールの ワクチン組成物製造における利用。 8.両親媒性化合物を中性脂質と組み合わせる請求項1〜7のいずれか一項に記 載の利用。 9.組み合わせる中性脂質の割合を少なくとも20%にする請求項8に記載の利用 。 10.中性脂質がジオレオイルホスファチジルエタノールアミン(DOPE)またはジオ レオイルホスファチジルコリン(DOPC)である請求項8または9に記載の利用。 11.両親媒性化合物をリポソーム形で水性環境中に懸濁させる請求項1〜10のい ずれか一項に記載の利用。 12.カチオン性基に結合したステロール由来の親油性基を含む両親媒性化合物の ワクチン投与用アジュバントとしての利用。 13.両親媒性化合物が 3β-[N-(N',N'-ジメチルアミノエタン)カルバモイル]- コレステロールである請求項12に記載の利用。 14.両親媒性化合物を中性脂質と組み合わせる請求項12または 13に記載の利用。 15.少なくとも一種の抗原を含むワクチン組成物において、カチオン性基に結合 したステロール由来の親油性基を有する少なくとも一種の両親媒性化合物をさら に含むことを特徴とするワクチン組成物。 16.親油性基がコレステロール誘導体である請求項15に記載のワクチン組成物。 17.両親媒性化合物が 3β-[N-(N',N'-ジメチルアミノエタン)カルバモイル]- コレステロールである請求項15または16に記載のワクチン組成物。 18.両親媒性化合物が少なくとも一種の抗原を含むリポソームの形の請求項15〜 17のいずれか一項に記載のワクチン組成物。 19.両親媒性化合物を中性脂質と組み合わせる請求項15〜18のいずれか一項に記 載のワクチン組成物。 20.少なくとも一種のインフルエンザウィルス抗原を含む請求項15〜19のいずれ か一項に記載のワクチン組成物。 21.少なくとも一種の抗原を哺乳動物に投与して哺乳動物における免疫応答を誘 導する方法において、極性基に結合したステロール由来の親油性基を有する少な くとも一種の両親媒性化合物をさらに投与することを特徴とする方法。 22.両親媒性化合物を抗原と同時に投与する請求項21に記載の方法。 23.抗原がインフルエンザウィルスの赤血球凝集素である請求項21または22のい ずれか一項に記載の方法。 24.カチオン性基に結合したステロール由来の親油性基を有する少なくとも一種 類の両親媒性化合物と、少なくとも一種の抗原とをワクチン処置において同時、 別々または時間をあけて使用する組合せ物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9413606A FR2726764B1 (fr) | 1994-11-14 | 1994-11-14 | Adjuvant pour composition vaccinale |
FR94/13606 | 1994-11-14 | ||
PCT/FR1995/001495 WO1996014831A1 (fr) | 1994-11-14 | 1995-11-14 | Adjuvant pour composition vaccinale |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11500409A true JPH11500409A (ja) | 1999-01-12 |
JP3923518B2 JP3923518B2 (ja) | 2007-06-06 |
Family
ID=9468771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51580096A Expired - Fee Related JP3923518B2 (ja) | 1994-11-14 | 1995-11-14 | ワクチン組成物用アジュバント |
Country Status (15)
Country | Link |
---|---|
US (2) | US6780421B1 (ja) |
EP (1) | EP0793484B1 (ja) |
JP (1) | JP3923518B2 (ja) |
CN (1) | CN1096851C (ja) |
AT (1) | ATE232720T1 (ja) |
AU (1) | AU706131B2 (ja) |
CA (1) | CA2205022C (ja) |
DE (1) | DE69529684T2 (ja) |
DK (1) | DK0793484T3 (ja) |
ES (1) | ES2187580T3 (ja) |
FR (1) | FR2726764B1 (ja) |
MX (1) | MX9703505A (ja) |
NZ (1) | NZ297032A (ja) |
PT (1) | PT793484E (ja) |
WO (1) | WO1996014831A1 (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0902682A2 (en) | 1996-05-08 | 1999-03-24 | Nika Health Products Limited | Cationic virosomes as transfer system for genetic material |
DE19631189A1 (de) * | 1996-08-02 | 1998-02-05 | Max Delbrueck Centrum | Neuartige kationische Amphiphile für den liposomalen Gentransfer |
FR2781160B1 (fr) * | 1998-07-03 | 2000-08-18 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire |
US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
WO2000011181A1 (en) | 1998-08-20 | 2000-03-02 | Connaught Laboratories Limited | NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA) |
DE60036698T2 (de) * | 1999-05-03 | 2008-07-24 | Sanofi Pasteur Ltd., Toronto | Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen |
FR2797188A1 (fr) * | 1999-08-04 | 2001-02-09 | Univ Paris Nord Laboratoire De | Composes lipidiques cationiques et leurs utilisation pour le transfert de substances d'interet therapeutique chargees negativement |
DK1227837T3 (da) | 1999-10-22 | 2008-09-15 | Aventis Pasteur | Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen |
EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
WO2001085932A2 (en) | 2000-05-10 | 2001-11-15 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
FR2881050B1 (fr) * | 2005-01-25 | 2007-02-23 | Sanofi Pasteur Sa | Dcchol chez les nouveaux-nes |
US20060165717A1 (en) * | 2005-01-25 | 2006-07-27 | Sanofi Pasteur | DCchol in newborns |
WO2007098607A1 (en) | 2006-03-03 | 2007-09-07 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
EP2772267B1 (en) | 2007-08-27 | 2016-04-27 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
ES2534671T3 (es) | 2007-09-11 | 2015-04-27 | University Of Guelph | Inmunógenos polisacáridos de la Clostridium difficile |
CN101827613A (zh) * | 2007-09-27 | 2010-09-08 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
DK2535428T3 (en) | 2007-10-01 | 2015-11-23 | Longhorn Vaccines & Diagnostics Llc | Biological prøvesamlings- and transport system, and methods of using |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
JP2011500730A (ja) | 2007-10-26 | 2011-01-06 | ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント | Tim−3を用いた治療および診断方法 |
US9789129B2 (en) | 2008-04-17 | 2017-10-17 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
CA2723918C (en) * | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
GB201116248D0 (en) * | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
EP2763698B1 (en) | 2011-10-06 | 2020-12-02 | ImmunoVaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
TWI672149B (zh) | 2012-09-21 | 2019-09-21 | 美商Pds生技公司 | 改良之疫苗組成物及使用方法 |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
CN108350051A (zh) | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 |
EP3374383A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES |
KR20180085736A (ko) | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
AU2016354590B2 (en) | 2015-11-13 | 2023-11-23 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4971803A (en) * | 1985-04-08 | 1990-11-20 | California Institute Of Technology | Lamellar vesicles formed of cholesterol derivatives |
NZ241926A (en) * | 1988-08-25 | 1993-08-26 | Liposome Co Inc | Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen |
US5100662A (en) | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
WO1993014744A1 (en) * | 1992-02-04 | 1993-08-05 | Chiron Corporation | Non-toxic lipid vaccine formulations |
FR2732895B1 (fr) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament |
-
1994
- 1994-11-14 FR FR9413606A patent/FR2726764B1/fr not_active Expired - Fee Related
-
1995
- 1995-11-14 AU AU41802/96A patent/AU706131B2/en not_active Ceased
- 1995-11-14 CN CN95196601A patent/CN1096851C/zh not_active Expired - Fee Related
- 1995-11-14 AT AT95940309T patent/ATE232720T1/de active
- 1995-11-14 WO PCT/FR1995/001495 patent/WO1996014831A1/fr active IP Right Grant
- 1995-11-14 PT PT95940309T patent/PT793484E/pt unknown
- 1995-11-14 ES ES95940309T patent/ES2187580T3/es not_active Expired - Lifetime
- 1995-11-14 EP EP95940309A patent/EP0793484B1/fr not_active Expired - Lifetime
- 1995-11-14 US US08/836,576 patent/US6780421B1/en not_active Expired - Fee Related
- 1995-11-14 NZ NZ297032A patent/NZ297032A/xx not_active IP Right Cessation
- 1995-11-14 DE DE69529684T patent/DE69529684T2/de not_active Expired - Lifetime
- 1995-11-14 JP JP51580096A patent/JP3923518B2/ja not_active Expired - Fee Related
- 1995-11-14 MX MX9703505A patent/MX9703505A/es not_active IP Right Cessation
- 1995-11-14 CA CA002205022A patent/CA2205022C/fr not_active Expired - Fee Related
- 1995-11-14 DK DK95940309T patent/DK0793484T3/da active
-
2004
- 2004-04-29 US US10/834,616 patent/US20050002952A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69529684D1 (en) | 2003-03-27 |
CN1168629A (zh) | 1997-12-24 |
ES2187580T3 (es) | 2003-06-16 |
MX9703505A (es) | 1997-07-31 |
EP0793484B1 (fr) | 2003-02-19 |
EP0793484A1 (fr) | 1997-09-10 |
WO1996014831A1 (fr) | 1996-05-23 |
PT793484E (pt) | 2003-06-30 |
ATE232720T1 (de) | 2003-03-15 |
AU4180296A (en) | 1996-06-06 |
DE69529684T2 (de) | 2003-09-18 |
FR2726764B1 (fr) | 1997-01-31 |
US20050002952A1 (en) | 2005-01-06 |
FR2726764A1 (fr) | 1996-05-15 |
JP3923518B2 (ja) | 2007-06-06 |
DK0793484T3 (da) | 2003-06-02 |
US6780421B1 (en) | 2004-08-24 |
NZ297032A (en) | 1999-11-29 |
CA2205022C (fr) | 2009-12-22 |
CN1096851C (zh) | 2002-12-25 |
AU706131B2 (en) | 1999-06-10 |
CA2205022A1 (fr) | 1996-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3923518B2 (ja) | ワクチン組成物用アジュバント | |
EP0356339B1 (en) | Influenza vaccine and novel adjuvants | |
US8673285B2 (en) | Sphingoid polyalkylamine conjugates for vaccination | |
US4196191A (en) | Biological preparations | |
JP5775451B2 (ja) | インフルエンザを処置するための組成物および方法 | |
US20190275145A1 (en) | Particulate vaccine formulations | |
US4148876A (en) | Biological preparations | |
US7906122B2 (en) | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination | |
JP2997073B2 (ja) | 鼻腔内または吸入投与用ワクチン製剤およびその製造方法 | |
TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
JP2001523216A (ja) | 新規のアジュバント組成物と、それからなるワクチン製剤 | |
CA1079634A (en) | Antigens bound to exterior surface of microvesicles | |
WO1992003162A1 (en) | Vaccines | |
WO1990001948A1 (en) | Influenza vaccine and novel adjuvants | |
CN116514671A (zh) | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 | |
Thibodeau | Immunosome technology to improve antigen presentation for efficient and safe viral vaccines | |
Pietrobon et al. | Lipopeptides and Their Effects on the Immune System Use as Vaccine Components | |
IL172464A (en) | Couplings of polyalkylamine sphingoid for vaccination | |
JP2004161781A (ja) | 経口ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060207 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060209 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060927 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070123 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070222 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110302 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120302 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140302 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |